| Diffuse Large B-Cell Lymphoma
Epkinly vs Zynlonta
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Epkinly vs Zynlonta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZynlonta has a higher rate of injection site reactions vs Epkinly based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zynlonta but not Epkinly, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Epkinly
Zynlonta
At A Glance
SC injection
Every 1-4 weeks
CD20xCD3 bispecific antibody
IV infusion
Every 3 weeks
CD19-directed antibody-drug conjugate
Indications
- Diffuse Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Lymphoma, Follicular
- Diffuse Large B-Cell Lymphoma
Dosing
Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (monotherapy) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (+ lenalidomide and rituximab) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg monthly for Cycles 4-12 with lenalidomide 20 mg (Days 1-21) and rituximab 375 mg/m2 (Cycles 1-5); total 12 cycles or until progression.
Diffuse Large B-Cell Lymphoma 0.15 mg/kg IV over 30 minutes every 3 weeks for 2 cycles, then 0.075 mg/kg every 3 weeks for subsequent cycles; premedicate with dexamethasone 4 mg orally or IV twice daily for 3 days beginning the day before administration.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) CRS, fatigue, injection site reactions, musculoskeletal pain, pyrexia, abdominal pain, nausea, diarrhea, rash, upper respiratory tract infections, constipation, pneumonia, COVID-19, fever, cough, headache
Serious CRS, infections (sepsis, COVID-19, pneumonia, upper respiratory tract infections), pleural effusion, febrile neutropenia, fever, ICANS
Postmarketing Hemophagocytic Lymphohistiocytosis (HLH)
Most common (>20%) Thrombocytopenia, increased GGT, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edema, nausea, musculoskeletal pain.
Serious Febrile neutropenia, pneumonia, edema, pleural effusion, sepsis.
Postmarketing Telangiectasia, cutaneous collagenous vasculopathy, blister, rash vesicular.
Pharmacology
Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager (humanized IgG1) that simultaneously binds CD3 on T-cells and CD20 on lymphoma and healthy B-lineage cells, activating T-cells, inducing cytokine release, and causing B-cell lysis; in combination with rituximab it also mediates NK cell antibody-dependent cellular cytotoxicity (ADCC).
Loncastuximab tesirine-lpyl is a CD19-directed antibody-drug conjugate (ADC); upon binding to CD19, the conjugate is internalized and releases SG3199, a PBD dimer alkylating agent that forms cytotoxic DNA interstrand crosslinks, inducing cell death in B-lineage cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Epkinly
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Zynlonta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Epkinly
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zynlonta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Epkinly
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Zynlonta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGenmab Patient Assistance Program: Epkinly
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableADVANCING Patient Support Patient Assistance Program: Zynlonta
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EpkinlyView full Epkinly profile
ZynlontaView full Zynlonta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.